 |
|
Molecular pathway appears crucial in development of pulmonary fibrosis
December 13, 2007Discovery may provide new therapeutic target for dangerous lung disease
A study led by Massachusetts General Hospital (MGH) researchers may have found a key mechanism underlying idiopathic pulmonary fibrosis (IPF), a usually fatal lung disease for which transplantation is the only successful treatment. The investigators found that a specific molecular pathway appears responsible for key aspects of the scarring of lung tissue that characterizes IPF, the cause of which is currently unknown. The results will appear in the January issue of Nature Medicine and have received early online release.
"Identifying the key role of this pathway in the development of fibrosis gives us an exciting new target for devising treatments," says Andrew Tager, MD, of the MGH Pulmonary and Critical Care Unit, who led the study. "An agent that blocks this pathway is already being developed as a potential cancer treatment, and we're hoping to be able to test it in our animal model of IPF to determine whether it might be a candidate for trials in patients."
About 50,000 new cases of IPF are diagnosed in the U.S. each year, primarily in people aged 50 to 75. While some patients may survive for extended periods, in others the diseases progresses rapidly, leading to death in an average of 3 to 5 years. Theories about the cause of IPF previously focused on chronic inflammation of the lungs, but recent evidence has suggested that an abnormal healing response to some sort of lung injury may be responsible.
The primary characteristic of IPF is scarring (fibrosis) of the lung surface, rendering it unable to transmit oxygen into the bloodstream. In any part of the body, scarring occurs when cells called fibroblasts, an important part of normal wound healing, make collagen to reinforce the healing matrix that forms over damaged tissue. Normally scarring is limited, but if too many fibroblasts travel to the site of an injury, large amounts of collagen can be deposited, producing excessive, fibrotic scarring. Fibroblasts are known to be present in affected lung tissue in IPF, and previous studies showed that the activity of factors that attract fibroblasts to the site of an injury rises with the severity of the disease. The current study was designed to determine which specific "chemoattractants" were associated with IPF, something not previously known.
Analysis of fluid from the lung surfaces of a mouse model of pulmonary fibrosis suggested that the activity of lysoposphatidic acid (LPA), acting through its receptor LPA1, was responsible for attracting fibroblasts in the disorder. This association was supported by the fact that a strain of mice lacking the gene for LPA1 did not develop pulmonary fibrosis when treated with a compound that usually causes the disease in the animals. Lung fluid samples from human IPF patients not only had significantly higher levels of LPA than control samples, laboratory tests showed that patient samples attracted fibroblasts while fluid from controls did not. In addition, an agent that blocks the LPA1 receptor eliminated the ability of fluid from IPF patients to attract fibroblasts.
"These results indicate that the LPA-LPA1 pathway is responsible for the abnormal migration of fibroblasts into the lungs in IPF, an absolutely crucial step in the development of fibrosis," says Andrew Luster, MD, PhD, senior author of the study. "This pathway appears to be involved in several steps in the development of fibrosis, including the leaking of blood vessels, which is why the LPA1 knockout mice are so dramatically protected. If we're right, then targeting this pathway should be a very exciting new therapeutic strategy for IPF." Luster is director of the MGH Center for Immunology and Inflammatory Disease (CIID) and a professor of Medicine at Harvard Medical School (HMS). Tager is also associated with the MGH CIID and has opened a clinic focused on pulmonary fibrosis and related lung diseases. He is an assistant professor of Medicine at HMS.
Massachusetts General Hospital
About 50,000 new cases of IPF are diagnosed in the U.S. each year, primarily in people aged 50 to 75. While some patients may survive for extended periods, in others the diseases progresses rapidly, leading to death in an average of 3 to 5 years. Theories about the cause of IPF previously focused on chronic inflammation of the lungs, but recent evidence has suggested that an abnormal healing response to some sort of lung injury may be responsible.
The primary characteristic of IPF is scarring (fibrosis) of the lung surface, rendering it unable to transmit oxygen into the bloodstream. In any part of the body, scarring occurs when cells called fibroblasts, an important part of normal wound healing, make collagen to reinforce the healing matrix that forms over damaged tissue. Normally scarring is limited, but if too many fibroblasts travel to the site of an injury, large amounts of collagen can be deposited, producing excessive, fibrotic scarring. Fibroblasts are known to be present in affected lung tissue in IPF, and previous studies showed that the activity of factors that attract fibroblasts to the site of an injury rises with the severity of the disease. The current study was designed to determine which specific "chemoattractants" were associated with IPF, something not previously known.
Analysis of fluid from the lung surfaces of a mouse model of pulmonary fibrosis suggested that the activity of lysoposphatidic acid (LPA), acting through its receptor LPA1, was responsible for attracting fibroblasts in the disorder. This association was supported by the fact that a strain of mice lacking the gene for LPA1 did not develop pulmonary fibrosis when treated with a compound that usually causes the disease in the animals. Lung fluid samples from human IPF patients not only had significantly higher levels of LPA than control samples, laboratory tests showed that patient samples attracted fibroblasts while fluid from controls did not. In addition, an agent that blocks the LPA1 receptor eliminated the ability of fluid from IPF patients to attract fibroblasts.
"These results indicate that the LPA-LPA1 pathway is responsible for the abnormal migration of fibroblasts into the lungs in IPF, an absolutely crucial step in the development of fibrosis," says Andrew Luster, MD, PhD, senior author of the study. "This pathway appears to be involved in several steps in the development of fibrosis, including the leaking of blood vessels, which is why the LPA1 knockout mice are so dramatically protected. If we're right, then targeting this pathway should be a very exciting new therapeutic strategy for IPF." Luster is director of the MGH Center for Immunology and Inflammatory Disease (CIID) and a professor of Medicine at Harvard Medical School (HMS). Tager is also associated with the MGH CIID and has opened a clinic focused on pulmonary fibrosis and related lung diseases. He is an assistant professor of Medicine at HMS.
Massachusetts General Hospital
Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News RSSCommon weed could provide clues on aging and cancer
A common weed and human cancer cells could provide some very uncommon details about DNA structure and its relationship with telomeres and how they affect cellular aging and cancer, according to a team led by scientists from Texas A&M University and the University of Cincinnati (UC).
New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas
Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation.
Pitt team first to profile genes in acutely ill idiopathic pulmonary fibrosis patients
The first findings from a one-of-a-kind, patient-driven effort to provide lung tissue for research might help doctors predict when patients with idiopathic pulmonary fibrosis (IPF) are becoming dangerously ill and also could point the way to interventions that could sustain them until life-saving transplants can be performed.
Protein may be strongest indicator of rare lung disease, study shows
Researchers at the University of Cincinnati (UC) have discovered a protein in the lungs that can help in determining progression of the rare lung disease Idiopathic Pulmonary Fibrosis (IPF).
Large clinical trial finds pirfenidone may help lung function in IPF patients
A large, well-controlled, multi-national clinical trial program has demonstrated the effectiveness and safety of what may become the first FDA-approved medicine for idiopathic pulmonary fibrosis, or IPF.
UT Southwestern researchers identify gene linked to inherited form of fatal lung disease
Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said.
Double threat: Deadly lung disease also linked to heart attacks
Patients with idiopathic pulmonary fibrosis (IPF) are three times as likely to experience severe coronary events-including heart attacks-than people without the disease.
Note to people with scarred and stiffened lungs: Monitor your sleep before severe fatigue sets in
Family, friends and neighbors remember Lisa Sandler Spaeth as an active mother of two in Potomac, Md., with a lot on the go, juggling her son's baseball games and her daughter's horseback-riding lessons with numerous committee obligations, organizing women's activities at her local synagogue.
Biomarkers identified for idiopathic pulmonary fibrosis
The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.
UCSF marks a milestone with 500th transplant in heart and lung program
UCSF marked a milestone this week with the 500th procedure in its Thoracic Transplant Program, which specializes in transplantation of the heart and lung.
More Pulmonary Fibrosis Current Events and Pulmonary Fibrosis News Articles
 |
The Official Patient's Sourcebook on Idiopathic Pulmonary Fibrosis by James N. Parker (Author) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to idiopathic pulmonary fibrosis (also alveolocapillary block; cryptogenic fibrosing alveolitis; diffuse fibrosing alveolitis; fibrosing alveolitis; Hamman-Rich syndrome; idiopathic diffuse interstitial pulmonary fibrosis), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various... |
 |
Understanding Lung Disease: Pulmonary Fibrosis Part of the award winning public television series Healthy Body/Healthy Mind. Pulmonary Fibrosis is a set of diseases that cause progressive scarring inside the lungs. Over time the lungs are slowly replaced with scar tissue, which causes airways to restrict airflow, making it difficult to breath and to get enough oxygen. Doctors, patients and researchers are hoping clinical trials will lead to a drug that prevents lung function from worsening ultimately allowing patients to live longer. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Pulmonary Fibrosis Awareness Ribbon Mouse Pad by MyHeritageWear.com The Pulmonary Fibrosis Ribbon proudly displayed on a mouse pad. There is no better way to achieve awareness for the meaning of the Pulmonary Fibrosis Ribbon than to display it on your mouse pad for everyone to see. The mouse pad measures at 9.25 x 7.75, it is machine washable, and the colors will not fade or run. Start gaining awareness today by presenting your Pulmonary Fibrosis Ribbon mouse pad at work or at home. It is certain to keep your mouse rolling in style all while gaining support and awareness! |
 |
Understanding Lung Disease: Pulmonary Fibrosis Directed By: (c) Information Television Network |
![Thorwald / Pulmonary Fibrosis [Explicit]](http://ecx.images-amazon.com/images/I/41anx1tCcwL._SL160_.jpg) |
Thorwald / Pulmonary Fibrosis [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
 |
Idiopathic Pulmonary Fibrosis Medical Guide by Qontro Medical Guides (Author) The Idiopathic Pulmonary Fibrosis Medical Guide is a publication which has been designed to better help readers understand Idiopathic Pulmonary Fibrosis. This Qontro Medical Guide has been designed with the reader in mind, and is a useful information source for readers at all levels looking to learn more about Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis Medical Guide is highly recommended for those interested in understanding and learning more about Idiopathic Pulmonary Fibrosis. |
 |
Advances in Pulmonary Fibrosis by John Simpson (Author), Ann Millar (Author) Recent years have seen renewed interest in diffuse parenchymal lung diseases (DPLDs), which were formerly referred to as interstitial lung diseases (ILDs). This is reflected in the publication of many important and groundbreaking papers in this field. Knowledge, and easy access to it, is the key to understanding pulmonary fibrosis. Providing reviews of the published medical literature of the past year, Advances in Pulmonary Fibrosis summarizes some of the most important new developments in the field. The book has been carefully designed so that key messages can be extracted by reading only the Background and Interpretations sections of each chapter. Providing more detailed information, the Comment sections generally start with an outline of the methods used, followed by a more... |
 |
Chronic Respiratory Disorders (118) CD-ROM by Concept Media, a division of Jobson Medical Information LLC 5 CD series including these programs: [118.1] Chronic Obstructive Pulmonary Disease; [118.2] Cystic Fibrosis; |
|
|
Compres Of Pulmonary Parenchyma [Explicit] Thorwald / Pulmonary Fibrosis (Primary Contributor) |
|
Understanding Lung Disease: Pulmonary Fibrosis Starring: Information Television Network |
| © 2009 BrightSurf.com |